St. Jude gets CE Mark, FDA nod for HIFU cardiac ablation system

St. Jude Medical has received European CE Mark approval and FDA clearance for the Epicor LP cardiac ablation system, a second generation technology that uses high-intensity focused ultrasound (HIFU) for cardiac ablation procedures.

In surgical ablation performed with a HIFU energy source, the company said that the energy is focused from outside a beating heart. The treatment has been designed to create precise and complete lines of cardiac tissue ablation to block chaotic electrical impulses. HIFU energy is directed from outside the heart inward, minimizing the risk of unintended peripheral damage, according to the St. Paul, Minn.-based company.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.